Table 1.

Available ERT based medicaments for LSDs. In the reference column there are indicated either reference articles or clinical trial numbers referring to www.clinicaltrials.gov (accessed on 15 November 2021) web page.

LSDs	Affected Enzyme	Available ERT	Development Status	Reference
GD	Glucocerebrosidase	Imglucerase	Approved	[18]
		Velaglucerase	Approved
		Taliglucerase alpha	Approved
FD	α-Galactosidase A	Agalsidase alpa	Approved	[19]
		Agalsidase beta	Approved	NCT03018730
		PRX-102	Phase III	NCT02795676
				NCT03180840
PD	α-Glycosidase	Alglucosidase alpha	Approved	[20]
		Avalglucosidase alfa	Approved	[21]
		VAL-1221	Phase I-II	NCT02898753
		ATB200	Phase III	NCT03729362
MPS I	α-L-iduronidase	Laronidase	Approved	[22]
MPS II	Iduronate-2-sulfatase	Idursulfasa	Approved	[23]
		AGT-182	Phase I	NCT02262338
		JR-141	Approved	[24]
MPS III A B	Heparan N-sulphatase	rhHNS	Phase I-II	NCT01299727
	N-acetyl-glucosaminidase	BMN250	Phase I-II	NCT02754076
MPS VI	N-acetylgalactosamine-4-sulfatase	Galsufase	Approved	[24]
MLD	Arilsulphatase A	HGT1110	Phase I-II	NCT01887938
		TAK611	Phase II	NCT015128 [25]
NPA and NPB	Acid Sphingomyelinase	rh-ASM	Phase I	NCT00410566